Given that effective cytotoxic killing requires direct contact between CD8+ T cells and tumour cells, it has been increasingly recognized that different CD8+ T-cell distributions in the tumour microenvironment (TME) may elicit different responses to immunotherapy8,9. This evidence concerns the gene CD8A and neoplasm.